Amplia Therapeutics moves to next phase of pancreatic cancer treatment trial
–News Direct– Amplia Therapeutics Ltd (ASX:ATX) CEO Chris Burns joins Proactives Jonathan Jackson to discuss the companys busy quarter and what investors can expect over the coming months. Burns talks us through the completion of the Phase1B stage of the ACCENT clinical trial in advanced pancreatic cancer patients and the promising early signs of drug…